Literature DB >> 23259831

Current and potential treatments for cervical cancer.

Grace P C Yee1, Paul de Souza, Levon M Khachigian.   

Abstract

Cervical cancer is the third most common carcinoma in women worldwide. Despite increasing efforts to improve therapy in this disease, a significant proportion of women still die, mostly from recurrent or chemoresistant disease. This review discusses current treatments for early cervical cancer, advanced disease, and recurrent cervical cancer, and covers concurrent chemoradiation, neoadjuvant chemotherapy before surgery and radiation, single agent treatment, combination treatment, platinum-based and non-platinum based therapy. We also discuss promising therapeutics trategies for cervical cancer including targeted therapy, cell-based therapy, combined siRNA and chemotherapy, and immunotherapy.

Entities:  

Mesh:

Year:  2013        PMID: 23259831     DOI: 10.2174/1568009611313020009

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  43 in total

1.  Sex-determining region Y-related high mobility group box (SOX)-2 is overexpressed in cervical squamous cell carcinoma and contributes cervical cancer cell migration and invasion in vitro.

Authors:  Xiaohan Chang; Jing Zhang; Chenglin Huang; Xiaoao Pang; Qingshuang Luo; Huijie Zhang; Shulan Zhang
Journal:  Tumour Biol       Date:  2015-05-03

2.  Buformin suppresses proliferation and invasion via AMPK/S6 pathway in cervical cancer and synergizes with paclitaxel.

Authors:  Jing Li; Ling Chen; Qiuli Liu; Mei Tang; Yuan Wang; Jinjin Yu
Journal:  Cancer Biol Ther       Date:  2018-02-27       Impact factor: 4.742

3.  MicroRNA-320 suppresses cervical cancer cell viability, migration and invasion via directly targeting FOXM1.

Authors:  Can Shi; Zhenyu Zhang
Journal:  Oncol Lett       Date:  2017-07-21       Impact factor: 2.967

4.  HOTAIR enhanced aggressive biological behaviors and induced radio-resistance via inhibiting p21 in cervical cancer.

Authors:  Li Jing; Wang Yuan; Dong Ruofan; Yu Jinjin; Qiu Haifeng
Journal:  Tumour Biol       Date:  2014-12-31

5.  Analyses of the association between cervical cancer and osteoporosis/osteoporotic fracture: a cross-sectional study using KoGES HEXA data.

Authors:  Hyo Geun Choi; Jung Woo Lee; Chan Yang Min; Dae Myoung Yoo; Suk Woo Lee
Journal:  Int J Clin Oncol       Date:  2021-06-06       Impact factor: 3.402

6.  MLN4924, a Novel NEDD8-activating enzyme inhibitor, exhibits antitumor activity and enhances cisplatin-induced cytotoxicity in human cervical carcinoma: in vitro and in vivo study.

Authors:  Wei-Chou Lin; Kuan-Lin Kuo; Chung-Sheng Shi; June-Tai Wu; Ju-Ton Hsieh; Hong-Chiang Chang; Shih-Ming Liao; Chien-Tso Chou; Chih-Kang Chiang; Wei-Shuo Chiu; Tzu-Yuan Chiu; Yeong-Shiau Pu; I-Lin Ho; Zuo-He Wang; Shih-Chen Chang; Shing-Hwa Liu; Yung-Ming Jeng; Kuo-How Huang
Journal:  Am J Cancer Res       Date:  2015-10-15       Impact factor: 6.166

Review 7.  The potential applications of T cell receptor (TCR)-like antibody in cervical cancer immunotherapy.

Authors:  Sylvia Annabel Dass; Rehasri Selva Rajan; Gee Jun Tye; Venugopal Balakrishnan
Journal:  Hum Vaccin Immunother       Date:  2021-05-14       Impact factor: 3.452

8.  A mechanism of regucalcin knock-down in the promotion of proliferation and movement of human cervical cancer HeLa cells.

Authors:  Xiaolong Li; Yingwen Huang; Pengfei Wang; Wei Song; Qingmei Yao; Qiping Hu; Sufang Zhou
Journal:  Transl Cancer Res       Date:  2019-04       Impact factor: 1.241

9.  In vivo synergistic anti-tumor effect of paclitaxel nanoparticles combined with radiotherapy on human cervical carcinoma.

Authors:  YanXin Yu; Shan Xu; Hong You; YinJie Zhang; Bo Yang; XiaoYang Sun; LingLin Yang; Yue Chen; ShaoZhi Fu; JingBo Wu
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

10.  Antiproliferative effects and molecular mechanisms of troglitazone in human cervical cancer in vitro.

Authors:  Jinjun Ye; Li Yin; Peng Xie; Jianfeng Wu; Jian Huang; Guoren Zhou; Hanzi Xu; Emei Lu; Xia He
Journal:  Onco Targets Ther       Date:  2015-05-26       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.